18-012 - Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboStatus: open
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Treatment for Breast Cancer
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. IRB Number 18-012
SponsorsThis trial is sponsored by NSABP.
Providers Associated With This Trial
- Donna Lynn Dyess, M.D., F.A.C.S.Breast/Endocrine SurgeonProfessor of Surgery